美诺华：全资子公司获得厄贝沙坦氢氯噻嗪片药品注册证书

Core Viewpoint - Meinuo Pharma has received approval from the National Medical Products Administration for the registration of Irbesartan Hydrochlorothiazide tablets, enhancing its market competitiveness and expanding its cardiovascular product pipeline [1] Group 1 - Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Irbesartan Hydrochlorothiazide tablets [1] - The drug is indicated for the treatment of primary hypertension, which addresses a significant health issue [1] - The approval allows the company to produce and sell the drug in the domestic market, positively impacting its operational development [1]